The Effect of Exenatide on Fasting Bile Acids
- Registration Number
- NCT04303819
- Lead Sponsor
- Beijing Chao Yang Hospital
- Brief Summary
Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were compared before and after exenatide treatment and correlation analysis between changes of FTBAs and glycemic parameters.
- Detailed Description
Newly diagnosed T2DM participants without hypoglycemic drugs intake were retrospective analyzed. Plasma total bile acids in fasting state (FTBAs) and other parameters were tested at baseline. Then exenatide were applied to the T2DM participants for 12 weeks. FTBAs and glycemic parameters were measured again after exenatide treatment, and correlation analysis between changes of FTBAs and glycemic parameters were conducted to investigate the role of BAs in the glycemic control effect of exenatide.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 38
- Newly diagnosed T2DM patients
- History of hepatobiliary or pancreatic diseases
- History of anti-diabetic drugs intake
- Change of anti-dyslipidemia therapy regimen
- Estimated glomerular filtration rate less than 60 mL/min/1.73 m^2
- Pregnancy
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description newly diagnosed T2DM participants Exenatide treatment newly diagnosed T2DM participants without anti-diabetic drugs intake
- Primary Outcome Measures
Name Time Method Plasma total bile acids in fasting state 12 weeks reported in μmol/L
- Secondary Outcome Measures
Name Time Method fasting plasma glucose 12 weeks reported in mmol/L
Glycated hemoglobin A1c 12 weeks reported in %
C-peptide 12 weeks reported in mU/L
Fasting serum insulin 12 weeks reported in mU/L
Body mess index 12 weeks reported in kg/m\^2
Trial Locations
- Locations (1)
Beijing Chao-yang hospital
🇨🇳Beijing, China